Literature DB >> 18423458

Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro.

Merja Bläuer1, Päivi H Rovio, Timo Ylikomi, Pentti K Heinonen.   

Abstract

OBJECTIVE: To determine the effect of 1,25(OH)(2)D(3) and 25(OH)D(3) vitamin D derivates on the growth of leiomyoma and myometrial cells in vitro.
DESIGN: In vitro study.
SETTING: Cell biology research laboratory. PATIENT(S): Six premenopausal women with uterine leiomyomas undergoing hysterectomy. INTERVENTION(S): Samples of leiomyomas and normal myometrial tissue were obtained, and paired cultures were established. MAIN OUTCOME MEASURE(S): A colorimetric crystal violet assay to determine the effect of 1,25(OH)(2)D(3) and 25(OH)D(3) on cell growth. RESULT(S): In both myometrial and leiomyoma cells, 0.1 nM physiologic level of 1,25(OH)(2)D(3) inhibited growth by 12% when compared with controls. The growth inhibition was concentration dependent; the highest concentration of 1,25(OH)(2)D(3) (100 nM) inhibited growth by 62% in both cell types. All the differences were statistically significant. A slight stimulation (<4%) of cell proliferation was observed with the lowest 25(OH)(2)D(3) concentrations. When treated with either a 500 nM or 1000 nM concentration of the compound, the growth of both cell types fell to approximately 50% of that of the control cultures, and the level of inhibition with the latter concentration was statistically significant. CONCLUSION(S): Both myometrial and leiomyoma cell growth in vitro was effectively inhibited by 1,25(OH)(2)D(3). Vitamin D may play a role in the growth of uterine leiomyomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423458     DOI: 10.1016/j.fertnstert.2008.02.136

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  38 in total

1.  1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.

Authors:  Sunil K Halder; Chakradhari Sharan; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2012-04-19       Impact factor: 4.285

Review 2.  Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy.

Authors:  Mostafa A Borahay; Ayman Al-Hendy; Gokhan S Kilic; Darren Boehning
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

3.  1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells.

Authors:  Sunil K Halder; J Shawn Goodwin; Ayman Al-Hendy
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

4.  Is the observed association between dairy intake and fibroids in African Americans explained by genetic ancestry?

Authors:  Lauren A Wise; Julie R Palmer; Edward Ruiz-Narvaez; David E Reich; Lynn Rosenberg
Journal:  Am J Epidemiol       Date:  2013-07-03       Impact factor: 4.897

5.  1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells.

Authors:  Sunil K Halder; Kevin G Osteen; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2013-12-26       Impact factor: 4.285

6.  Vitamin D and uterine leiomyoma among a sample of US women: Findings from NHANES, 2001-2006.

Authors:  Susanna D Mitro; Ami R Zota
Journal:  Reprod Toxicol       Date:  2015-06-03       Impact factor: 3.143

7.  Can vitamin D reduce the risk of uterine fibroids?

Authors:  Ayman Al-Hendy; Marwa Badr
Journal:  Womens Health (Lond)       Date:  2014-07

Review 8.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

9.  Vitamin d and the risk of uterine fibroids.

Authors:  Donna Day Baird; Michael C Hill; Joel M Schectman; Bruce W Hollis
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

Review 10.  Epidemiology of Uterine Fibroids: From Menarche to Menopause.

Authors:  Lauren A Wise; Shannon K Laughlin-Tommaso
Journal:  Clin Obstet Gynecol       Date:  2016-03       Impact factor: 2.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.